Health Care & Life Sciences » Pharmaceuticals | Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc. | Ownership

Companies that own Adamas Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Point72 Asset Management LP
2,272,115
8.36%
235,515
0.26%
06/30/2018
SSgA Funds Management, Inc.
2,191,792
8.06%
-611,315
0%
06/30/2018
Invesco Advisers, Inc.
1,954,258
7.19%
270,144
0.03%
06/30/2018
BlackRock Fund Advisors
1,687,911
6.21%
289,256
0%
06/30/2018
Broadfin Capital LLC
1,417,121
5.21%
281,918
4.49%
06/30/2018
Macquarie Investment Management Business Trust
1,307,810
4.8%
142,912
0.06%
06/30/2018
Perceptive Advisors LLC
1,084,159
3.99%
454,159
0.56%
06/30/2018
Fidelity Management & Research Co.
1,073,702
3.95%
-339,500
0%
06/30/2018
The Vanguard Group, Inc.
956,820
3.52%
45,472
0%
06/30/2018
Henderson Global Investors Ltd.
916,986
3.37%
-3,673
0.01%
06/30/2018

About Adamas Pharmaceuticals

View Profile
Address
1900 Powell Street
Emeryville California 94608
United States
Employees -
Website http://www.adamaspharma.com
Updated 07/08/2019
Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.